Clinical trial · Observational
Mucin Glycosylating Enzymes in Head and Neck Cancers
Expression of Mucin Glycosylating Enzymes in Head and Neck Cancers and Its Correlation With Clinico-pathological Parameters.
NCT01976377CI-TRIAL-00025166unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Head and neck squamous cell carcinoma(HNSCC) is the fourth common malignancy in Taiwan. It accounts for 5.8% of all cancers and causes 2,463 deaths per year. Aberrant glycosylation is the hallmark of most human cancers, including HNSCC, and affects many cellular properties. This study is aimed at exploring the role of mucin glycosylating enzymes in HNSCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glycosyltion Enzymes and Function Abnormalities | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Stage I, II, III, IV HNSCC
- description
- Stage I, II, III, IV HNSCC reveive treatment in NTUH
Primary outcomes (1)
- measure
- Measure the expression of mucin glycosylating in head and neck cancer
- timeFrame
- 1~5 years after patient received surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Head and neck cancer patients receiving operation in National Taiwan University Hospital Exclusion Criteria: * Recurrence or non-operable patients
References
Publications (0)
Data not yet available
No reference posted for this study.